HBB rs34598529: Understanding Beta-Plus Thalassemia Carrier Status
The rs34598529 variant in the HBB gene is a genetic change known as a splice-donor mutation. It is associated with beta-plus thalassemia, a condition that affects the production of hemoglobin, and is primarily studied as a carrier marker in specific Mediterranean and Middle Eastern populations.
What each genotype means
Typical HBB genotype
This genotype represents the common, non-mutated sequence at this position in the HBB gene. Individuals with this genotype do not carry this specific beta-thalassemia mutation.
This is the most common genotype found in the general population.
Beta thalassemia carrier
This genotype indicates you are a carrier of the beta-plus thalassemia mutation, historically known as IVS-I-110 G>A. Carriers are typically asymptomatic but may show mild hematological changes; please consult a clinician to discuss what this means for your health or family planning.
This genotype is most frequently observed in individuals of Mediterranean and Middle Eastern ancestry, with carrier frequencies reaching up to 5% in certain regions.
Likely beta thalassemia intermedia
This genotype indicates the presence of two copies of the beta-plus thalassemia mutation. This is associated with a higher likelihood of developing beta thalassemia intermedia, a condition characterized by variable clinical symptoms and potential anemia; please discuss these findings with a medical professional or genetic counselor.
This genotype is rare in the general population and is primarily identified in specific populations where the carrier frequency is elevated.
What is the rs34598529 Variant?
The rs34598529 variant, historically referred to as IVS-I-110 G>A or c.93-21G>A, is a specific change in the DNA sequence of the HBB gene. Located within intron 1, this variant acts as a splice-donor mutation. In the process of gene expression, DNA is transcribed into RNA, which must then be 'spliced' to remove non-coding regions called introns. By altering the splice site, this variant can interfere with the correct assembly of the messenger RNA, leading to reduced or abnormal production of the beta-globin protein. Because it does not completely abolish protein production but rather reduces it, it is classified as a beta-plus thalassemia mutation. This means the body can still produce some functional hemoglobin, though often at levels lower than what is required for optimal red blood cell function.
The Role of the HBB Gene
The HBB gene provides the essential instructions for creating the beta-globin protein. Beta-globin is a critical subunit of hemoglobin, the complex protein found in red blood cells that is responsible for transporting oxygen from the lungs to the rest of the body. Hemoglobin is typically composed of two alpha-globin subunits and two beta-globin subunits. When the HBB gene carries a mutation like rs34598529, the resulting beta-globin protein may be produced in insufficient quantities or be structurally compromised. This imbalance can lead to the destruction of red blood cells or ineffective production, which are the hallmarks of thalassemia. Understanding the function of HBB is vital because it highlights why even small changes in the genetic code can have significant impacts on systemic oxygen transport and overall hematologic health.
Research and Clinical Associations
Research has long associated the rs34598529 variant with beta-plus thalassemia. Clinical evidence, including data from databases like ClinVar, indicates that individuals carrying this variant may exhibit symptoms ranging from mild anemia to more complex forms of thalassemia intermedia, depending on the presence of other genetic factors. The evidence strength for this variant as a pathogenic marker is well-established in the context of carrier screening. However, the clinical expression is highly variable. It is important to note that genetic associations are statistical in nature; the presence of this variant does not guarantee a specific clinical outcome. Individuals who are concerned about their carrier status or potential health implications should consult with a medical geneticist or a hematologist who can interpret these findings in the context of a complete clinical and family history.
Population Frequency and Distribution
The prevalence of the rs34598529 variant is not uniform across the globe; it is highly ancestry-specific. It is most frequently observed in populations from the Mediterranean and the Middle East, where historical selective pressures related to malaria may have influenced the frequency of hemoglobin variants. According to data from gnomAD, the allele frequency in non-Finnish European populations is approximately 0.0005. However, in specific regions of the eastern Mediterranean, this frequency can rise significantly, reaching up to 0.05 in certain cohorts. This uneven distribution underscores the importance of considering ancestral background when interpreting genetic test results. Because the variant is rare in many other global populations, it is often included in targeted carrier screening panels specifically designed for individuals with Mediterranean or Middle Eastern heritage.
Navigating Genetic Information
If you have identified this variant in your genetic data, it is essential to understand what you can and cannot do with this information. This data is for educational purposes and does not constitute a medical diagnosis. You cannot use this information to self-prescribe treatments or assume a specific health status. If you are a carrier, it simply means you carry one copy of the variant, which is typically asymptomatic but relevant for family planning. If you are concerned about your health or reproductive risks, the most appropriate step is to discuss these results with a qualified healthcare provider or a genetic counselor. They can provide context, order confirmatory clinical testing if necessary, and help you understand the implications for your health and your family. Always rely on professional medical guidance rather than direct-to-consumer genetic reports for clinical decision-making.
How common is this variant?
The rs34598529 variant is rare in the general population, with a frequency of approximately 0.0005 in non-Finnish Europeans, but it reaches frequencies up to 0.05 in specific eastern Mediterranean populations.
Frequently asked questions
What does it mean to be a carrier of HBB rs34598529?
Being a carrier means you have one copy of the variant and one typical copy of the HBB gene. Carriers are usually asymptomatic but may have mild hematologic changes and can pass the variant to their children.
Is rs34598529 the same as IVS-I-110?
Yes, rs34598529 is the modern rsID for the mutation historically known as IVS-I-110 G>A. Both terms refer to the same specific genetic change in the HBB gene.
Does having this variant mean I have thalassemia?
Not necessarily. Having one copy (carrier status) typically does not cause significant disease. Having two copies is associated with beta-plus thalassemia, but clinical severity can vary widely between individuals.
Should I be worried if I have this variant?
Genetic variants are common, and many people carry them without knowing. If you are concerned, the best course of action is to speak with a doctor or genetic counselor who can provide personalized medical advice.
Sources & further reading
Educational information only, last refreshed 10/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs34598529?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in HBB
This variant is a pathogenic mutation in the HBB gene associated with beta-thalassemia.
This variant is a pathogenic mutation in the HBB gene associated with hemoglobinopathies such as sickle cell disease.
This variant (c.20A>T, p.Glu7Val) causes the substitution of valine for glutamic acid in the beta-globin chain, leading to sickle cell trait or disease depending on zygosity.
Pathogenic variant (p.Glu6Val, HbS-Antilles) in HBB associated with sickle cell disease-like pathology.
Pathogenic nonsense mutation (c.118C>T / p.Gln40Ter / codon 39 nonsense) causing beta-zero thalassemia and classic carrier status (beta-thalassemia minor).
This variant, known as Hb C-Harlem, involves a double mutation in the HBB gene that can lead to sickle-beta-thalassemia-like phenotypes.